

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 2

**Listing of Claims:**

1. (Withdrawn) A method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal-derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder.
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 3

10. (Withdrawn) A method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, the composition being administered in an amount effective to cause proliferation of the cells and/or inhibit apoptosis of the cells of the tissue within the subject so as to thereby treat the disorder.
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Withdrawn) The method of claim 10, wherein the tissue is heart tissue and the cells are cardiomyocytes.
15. (Cancelled)
16. (Withdrawn) The method of claim 10, wherein the tissue is heart tissue and the cells are progenitors of cardiomyocytes or stem cells that differentiate to cardiomyocytes.
17. (Cancelled).

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 4

18. (Cancelled).
19. (Withdrawn) The method of claim 10, further comprising administering an amount of one or more of a human granulocyte-colony stimulating factor, a human stromal-derived factor-1, a human granulocyte macrophage-colony stimulating factor, a human interleukin-8, a human vascular endothelial growth factor, a human fibroblast growth factor, a human Gro family chemokine, human endothelial progenitor cells, or a pro-angiogenic agent, the amount, or if appropriate amounts, effective to cause proliferation of the cells and/or inhibit apoptosis of the cells of the tissue of the subject so as to thereby treat the disorder.
20. (Withdrawn) A composition comprising a human stromal-derived factor-1 and a human granulocyte-colony stimulating factor.
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Withdrawn) A method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 5

composition comprising an amount of an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, the composition being administered in an amount effective to inhibit apoptosis and/or cause proliferation of the cells of the tissue within the subject so as to thereby treat the disorder.

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 6

34. (Cancelled)

35. (Currently Amended) A method of treating a subject suffering from a disorder of a tissue involving loss or apoptosis of cells of the tissue which comprises administering to the subject ~~a composition comprising~~ an amount of an agent which induces activation of CXCR4, ~~the composition being administered in an amount~~ effective to cause proliferation of the cells or inhibit apoptosis of the cells of the tissue within the subject so as to thereby treat the subject.

36. (Previously Presented) The method of claim 35, wherein the tissue is heart tissue and the cells are cardiomyocytes.

37. (Previously Presented) The method of claim 36, wherein the agent is administered intramyocardially or intracoronarily via (a) a stent, (b) a scaffold, or (c) a slow-release formulation.

38. (Cancelled).

39. (Cancelled).

40. (Cancelled).

41. (Cancelled).

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 7

42. (Cancelled).

43. (Previously Presented) The method of claim 35, wherein the agent is administered intramyocardially.

44. (Previously Presented) The method of claim 35, wherein the agent is administered systemically.

45. (Currently Amended) The method of claim 35, wherein the agent comprises a human stromal-derived factor-1.

46. (Previously Presented) The method of claim 45, wherein the human stromal-derived factor-1 is human stromal-derived factor-1 $\alpha$ .

47. (Previously Presented) The method of claim 45, wherein the human stromal-derived factor-1 is human stromal-derived factor-1 $\beta$ .

48. (Previously Presented) The method of claim 45, wherein the human stromal-derived factor-1 is human stromal-derived factor-1 $\gamma$ .

49. (Previously Presented) The method of claim 36, wherein the disorder comprises myocardial infarction, congestive heart failure, chronic ischemia, ischemic disease, diabetic heart disease or cardiomyopathy.

Applicant : Silviu Itescu  
U.S. Serial No.: 10/693,480  
Filed : October 23, 2003  
Page 8

50. (Previously Presented) The method of claim 36, wherein the disorder comprises ischemic disease.
51. (New) The method of claim 43, wherein the agent is administered intramyocardially by direct injection into a myocardium.
52. (New) The method of claim 45, wherein the human stromal-derived factor-1 is human stromal-derived factor-1 $\alpha$ , human stromal-derived factor-1 $\beta$ , or human stromal-derived factor-1 $\gamma$ .